Figure 1. CD1d deficiency remodels the immune infiltrates in the TME in a manner that supports tumor control. (A) Bulk RNA-seq for pMacs isolated from WT or CD1d-KO mice. Left: Results of GSEA Hallmark pathway analysis showing top enriched gene More about this image found in CD1d deficiency remodels the immune infiltrates in the TME in a manner that...

Figure 2. Anti-CD1d reduces tumor growth and enhances anti-PD-1–induced tumor regression. (A and B) Mouse BMDMs (A) or human MDMs (B) were cultured with αCD1d or isotype and stimulated with IFN-γ or IL-4 as indicated (or left unstimulated, u). More about this image found in Anti-CD1d reduces tumor growth and enhances anti-PD-1–induced tumor regress...

Figure 3. CD1d controls the myeloid transcriptional program in the TME. (A–G) scRNA-seq was performed for myeloid cells enriched from EO771 tumors from WT and CD1d-KO mice at day 15 (n = 3 mice per condition). (A) Experimental setup and UMAP More about this image found in CD1d controls the myeloid transcriptional program in the TME. (A–G) scRNA-...

Figure 4. CD1d controls the transcriptional program and accumulation of inflammatory monocytes. (A) Violin plots showing the expression of the depicted genes in the myeloid clusters identified by scRNA-seq (as in Fig. 3, A and B ). (B) GSEAs More about this image found in CD1d controls the transcriptional program and accumulation of inflammatory ...

Figure 5. CD1d-associated gene signature correlates with clinical outcomes and response to immunotherapy in breast cancer patients. (A) UMAP plot of myeloid cell clusters (filtered for monocytes, TAMs, DCs, and pDCs) from human breast cancers ( More about this image found in CD1d-associated gene signature correlates with clinical outcomes and respon...

Figure 1. Pharmacokinetics of infused Tregs in the peripheral blood of type 1 diabetes patients. FACS-purified autologous Tregs were expanded ex vivo in medium containing deuterated glucose, which resulted in the enrichment of deuterium in the More about this image found in Pharmacokinetics of infused Tregs in the peripheral blood of type 1 diabete...

Figure 2. OrthoIL-2 3A10 is a selective but weak agonist for orthoIL-2R. (A) Experimental workflow for assessing function of 3A10 in vitro and in vivo. Created in BioRender. Tang (2026) https://BioRender.com/q07c632 . (B) Dose response of More about this image found in OrthoIL-2 3A10 is a selective but weak agonist for orthoIL-2R. (A) Experim...

Figure 3. OrthoIL-2 1G12 has higher potency but cross-reacts on wtIL-2R. (A) Dose response of IL-2–induced pSTAT5 in Tregs transduced with EV or orthoIL-2R. (B) Treg proliferation measured using CTV dilution. The data were collected in the More about this image found in OrthoIL-2 1G12 has higher potency but cross-reacts on wtIL-2R. (A) Dose re...

Figure 4. Engineering a tethered orthoIL-2–IL-2Rβ system. (A) Schematic of the tethered IL-2–IL-2R components tested. Created in BioRender. Tang (2026) https://BioRender.com/dayo897 . (B) Visualization of the four linkers used to tether More about this image found in Engineering a tethered orthoIL-2–IL-2Rβ system. (A) Schematic of the tethe...

Figure 5. RNA-seq analysis of engineered Tregs. (A) PC analysis of RNA-seq data of Treg cells expressing EV with or without IL-2, and Tregs expressing 1G12t or 3A10t. (B) Venn diagrams showing overlap of upregulated (left) and downregulated More about this image found in RNA-seq analysis of engineered Tregs. (A) PC analysis of RNA-seq data of T...

Figure 6. Function of Tregs expressing tethered 3A10-orthoIL-2R. (A) Experimental workflow for assessing function of 3A10 expressing Treg in vitro and in vivo. Created in BioRender. Tang (2026) https://BioRender.com/hloc6vm . (B) pSTAT5 in More about this image found in Function of Tregs expressing tethered 3A10-orthoIL-2R. (A) Experimental wo...

Figure 7. Safe engineering of the tethered orthoIL-2–IL-2R system. (A) Diabetes development in NOD.CD28KO mice that received 20,000 CD4⁺ BDC2.5Tg TCR transgenic T cells transduced with EV or 3A10t. Results shown are a summary of two independent More about this image found in Safe engineering of the tethered orthoIL-2–IL-2R system. (A) Diabetes deve...

Figure 1. Antibody modulates immune responses in the absence of cellular memory. (A) Experimental schematic for B–J. (B) Representative flow cytometry plots for GC B cells in mice pre-infused with 3BNC117 IgG2a (left, +Ab, pink, for B–J) or no More about this image found in Antibody modulates immune responses in the absence of cellular memory. (A) ...

Figure 2. Antibody-mediated effects require CD40L but not CR1/2. (A) Experimental schematic for B and C. (B) Plot shows the percentage of GC B cells of B220⁺ cells in mice pre-infused with 3BNC117 IgG2a in concert with anti-CD40L (maroon, for More about this image found in Antibody-mediated effects require CD40L but not CR1/2. (A) Experimental sc...

Figure 3. Enhanced magnitude of GC and PB compartments is dependent on FcγRs. (A) Experimental schematic for B–E and G and H. (B) Plot shows the percentage of GC B cells of B220⁺ cells in FcRα null mice pre-infused with 3BNC117 IgG2a (+Ab, More about this image found in Enhanced magnitude of GC and PB compartments is dependent on FcγRs. (A) Ex...

Figure 4. Antibody infusion elicits GC and PB compartments with reduced antigen-binding by an FcγR-independent mechanism. (A) Experimental schematic for B–L. (B) Plot shows the percentage of TM4-Core⁺ cells of GC B cells in FcRα null mice More about this image found in Antibody infusion elicits GC and PB compartments with reduced antigen-bindi...